In short
Capivasertib, a promising drug in cancer research, is currently being studied in various clinical trials for its potential to treat different types of cancer. These trials aim to evaluate the drug's effectiveness, safety, and how it interacts with other medications. The studies focus on breast cancer, lymphoma, and other solid tumors, offering hope for patients with advanced or resistant forms of these diseases.
At a glance
- Drug Name
- Capivasertib (also known as AZD5363)
- Mechanism of Action
- Selective inhibitor of AKT/PKB (protein kinase B) pathway
- Cancer Types Studied
- Breast cancer (HR+/HER2-), B-cell non-Hodgkin lymphoma, advanced solid tumors
- Administration
- Oral, typically 400mg twice daily, 4 days on/3 days off in 28-day cycles
- Combination Therapies
- Fulvestrant, Paclitaxel
- Key Outcome Measures
- Progression-free survival, Overall survival, Objective response rate, Time to next treatment
- Biomarkers
- ctDNA levels, PIK3CA/AKT1/PTEN alterations
- Safety Assessments
- Adverse events, Serious adverse events, Quality of life measures
What is Capivasertib?
Capivasertib, also known as AZD5363 or Truqap, is a promising new drug being studied for the treatment of various types of cancer. It is a type of medication called a kinase inhibitor, which means it works by blocking certain proteins in cancer cells that help them grow and survive.
How Capivasertib Works
Capivasertib specifically targets and inhibits a protein called AKT (also known as protein kinase B). AKT is an important part of a signaling pathway in cells that can become overactive in cancer, leading to uncontrolled cell growth and survival. By blocking AKT, capivasertib aims to slow down or stop the growth of cancer cells.
Cancers Treated with Capivasertib
Capivasertib is being studied in clinical trials for several types of cancer, including:
- Breast cancer: Particularly for patients with hormone receptor-positive (HR+) and HER2-negative breast cancer, as well as triple-negative breast cancer (TNBC)
- Prostate cancer: Specifically for patients with metastatic castration-resistant prostate cancer (CRPC)
- Lymphoma: Including various types of B-cell non-Hodgkin lymphoma
- Other solid tumors: Capivasertib is being investigated in patients with various advanced solid tumors
Clinical Trials and Research
Capivasertib is currently being studied in several clinical trials to determine its effectiveness and safety. Some key areas of research include:
- Combination therapy: Capivasertib is being tested in combination with other cancer treatments, such as hormone therapies (fulvestrant) for breast cancer and chemotherapy (paclitaxel) for triple-negative breast cancer
- Biomarker studies: Researchers are looking at whether certain genetic changes in tumors, such as AKT mutations, can predict which patients will respond best to capivasertib
- Early detection of cancer recurrence: One study is investigating whether capivasertib can help prevent cancer recurrence in patients who have detectable cancer DNA in their blood after initial treatment
Administration and Dosing
Capivasertib is typically given as an oral medication (taken by mouth) in the form of tablets. The dosing schedule can vary depending on the specific clinical trial and cancer type, but common schedules include:
- Taking the medication twice daily for 4 days, followed by 3 days off
- Taking the medication twice daily for 4 days each week, with 3 days off, as part of a 28-day cycle
The exact dose may be adjusted based on how well a patient tolerates the medication and their individual response to treatment.
Side Effects and Safety
As with all cancer treatments, capivasertib can cause side effects. While the full safety profile is still being studied in clinical trials, some potential side effects may include:
- Fatigue
- Nausea
- Diarrhea
- Changes in blood sugar levels
- Skin rash
It's important to note that not all patients will experience these side effects, and the severity can vary. Researchers are closely monitoring the safety and tolerability of capivasertib in ongoing clinical trials.
Future Prospects
Capivasertib shows promise in the treatment of various cancers, particularly in combination with other therapies. Ongoing research aims to:
- Determine the most effective dosing schedules and combinations with other treatments
- Identify which patients are most likely to benefit from capivasertib based on genetic markers in their tumors
- Explore its potential in preventing cancer recurrence in high-risk patients
As clinical trials progress, more information will become available about the effectiveness and safety of capivasertib in different cancer types and treatment settings.